Zobrazeno 1 - 10
of 729
pro vyhledávání: '"Peter K Kaiser"'
Autor:
Carl D Regillo, Peter K Kaiser, Michael S Ip, Yasha Modi, Edwin H Ryan, Paul M Karpecki, Caroline Baumal, Elizabeth Yeu, Lisa Nijm, Marjan Farid, Ronald Luke Rebenitsch, Terry Kim, Diana L Shechtman, Kelly Nichols, Justin Schweitzer, Mark T Dunbar, Mohammad R Rafieetary, Eric D Donnenfeld
Publikováno v:
BMJ Open Ophthalmology, Vol 8, Iss 1 (2023)
Background/aims With a paradigm shift in geographic atrophy (GA) treatments now available, establishing consensus on the identification and diagnosis of the disease along with considerations for management of patients with GA will assist eye care pro
Externí odkaz:
https://doaj.org/article/76350bb4a8d04ed78cde034003141e12
Autor:
Atsuro Uchida, Ming Hu, Amy Babiuch, Sunil K Srivastava, Rishi P Singh, Peter K Kaiser, Katherine Talcott, Aleksandra Rachitskaya, Justis P Ehlers
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218889 (2019)
PurposeTo evaluate optical coherence tomography angiography (OCTA) characteristics of choroidal neovascularization (CNV) in eyes requiring different treatment frequency of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-rel
Externí odkaz:
https://doaj.org/article/a3df795b8c054b94b20174fe3c9f97ec
Autor:
Rishi P Singh, Jonathan E Sears, Rumneek Bedi, Andrew P Schachat, Justis P Ehlers, Peter K Kaiser
Publikováno v:
International Journal of Ophthalmology, Vol 8, Iss 2, Pp 310-314 (2015)
AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR). METHODS: A retrospective consecutive case series was conducted for patients receiving or
Externí odkaz:
https://doaj.org/article/c1ab9114b1cf45ed962b8a12278937c0
Publikováno v:
Ophthalmology and Therapy. 12:985-998
SB11 (Byooviz™) is a ranibizumab biosimilar that acts as a vascular endothelial growth factor (VEGF)-A inhibitor. Stability data for unopened SB11 vials at room temperature are limited and no data are available for SB11 withdrawn into syringes (in-
Autor:
Varun Chaudhary, Gurkaran S. Sarohia, Mark R. Phillips, Dena Zeraatkar, Jim S. Xie, Keean Nanji, Reem A. Mustafa, Peter K. Kaiser, Anat Loewenstein, Sunir J. Garg, Sophie J. Bakri, Frank G. Holz, Sobha Sivaprasad, Mohit Bhandari, David H. Steel, Charles C. Wykoff
Publikováno v:
Ophthalmology Retina. 7:33-43
Publikováno v:
Retina. 42:2243-2250
Anti-vascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these im
Autor:
Joseph R. Abraham, Glenn J. Jaffe, Peter K. Kaiser, Stephanie J. Chiu, Jessica Loo, Sina Farsiu, Laurens Bouckaert, Vicken Karageozian, Melvin Sarayba, Sunil K. Srivastava, Justis P. Ehlers
Publikováno v:
Ophthalmology Retina. 6:1019-1027
Autor:
Eleonora M, Lad, David S, Boyer, Jeffrey S, Heier, Julie A, Kornfield, Baruch D, Kuppermann, Hugo, Quiroz-Mercado, Janine M, Aubel, Lisa S, Karageozian, Hampar L, Karageozian, Melvin A, Sarayba, Vicken H, Karageozian, Peter K, Kaiser
Publikováno v:
Ophthalmic Surgery, Lasers and Imaging Retina. 53:430-438
BACKGROUND AND OBJECTIVE: To explore the association between best-corrected visual acuity (BCVA) improvement and changes in microperimetry (MP) and color vision in patients with nonexudative age-related macular degeneration following administration o
Autor:
Keean Nanji, Gurkaran S. Sarohia, Jim Xie, Nikhil S. Patil, Mark Phillips, Dena Zeraatkar, Lehana Thabane, Robyn H. Guymer, Peter K. Kaiser, Sobha Sivaprasad, Srinivas R. Sadda, Charles C. Wykoff, Varun Chaudhary
Publikováno v:
Acta Ophthalmologica.
Autor:
Focke Ziemssen, Thomas A. Albini, Bahram Bodaghi, Nicolas Feltgen, Mayur R. Joshi, Richard Gale, Soumil Parikh, Iryna Lobach, Michael A Singer, Caroline R. Baumal, András Seres, Peter K. Kaiser
Publikováno v:
Ophthalmology Retina. 6:97-108
Purpose This analysis of the pivotal phase 3 HAWK and HARRIER trials aimed to provide insights on the timing of presentation, management, and outcomes of intraocular inflammation (IOI)-related adverse events (AEs), as reported by investigators in the